Recent genetic studies have highlighted the potential involvement of melatonin receptor 1 (MT 1 ) and melatonin receptor 2 (MT 2 ) in the pathogenesis of type 2 diabetes. Here, we report that mice lacking MT 1 (MT 1 KO) tend to accumulate more fat mass than WT mice and exhibit marked systemic insulin resistance. Additional experiments revealed that the main insulin signaling pathway affected by the loss of MT 1 was the activation of phosphatidylinositol-3-kinase (PI3K). Transcripts of both catalytic and regulatory subunits of PI3K were strongly downregulated within MT 1 KO mice. Moreover, the suppression of nocturnal melatonin levels within WT mice, by exposing mice to constant light, resulted in impaired PI3K activity and insulin resistance during the day, similar to what was observed in MT 1 KO mice. Inversely, administration of melatonin to WT mice exposed to constant light was sufficient and necessary to restore insulin-mediated PI3K activity and insulin sensitivity. Hence, our data demonstrate that the activation of MT 1 signaling at night modulates insulin sensitivity during the day via the regulation of the PI3K transcription and activity.
| INTRODUCTION
The hormone melatonin is secreted by the pineal gland during the dark portion of the day and is considered one of the main hormonal signals through which external light information is communicated to the rest of the body. 1 Although classically known for its function in the regulation of reproductive cycles, recent studies have implicated melatonin in the timing of a number of different physiological processes. 2 Among these, perhaps one of the most surprising is the role of melatonin in the regulation of blood glucose levels. Low levels of melatonin at night have been linked to metabolic abnormalities such as insulin resistance and type 2 diabetes (T2D). 3, 4 Moreover, the suppression of nocturnal melatonin by light at night has been associated with several pathologies including T2D. 5, 6 Melatonin communicates nightly timing cues through the activation of 2 G-protein-coupled receptors (GPCRs)-melatonin receptor 1 (MT 1 ) and melatonin receptor 2 (MT 2 ). Both MT 1 and MT 2 have been shown to activate several signaling pathways, most notably the Gi/cAMP and Gq/Phospholipase C (PLC)/Ca 2+ pathways. 1, 7 These receptors are expressed in a number of different peripheral tissues, and as such, function to modulate multiple aspects of human physiology (reviewed in ref. 8) . Recent genome-wide association studies have shown that polymorphisms in the genes encoding human melatonin receptors (MTNR1A and MTNR1B) are involved in the pathogenesis of T2D. [9] [10] [11] Variants in MTNR1B (MT 2 ) have been linked to impairments in both insulin secretion and increased fasting glucose levels, 9, 10 and variants in MTNR1A (MT 1 ) have been shown to be associated with an increased risk of developing polycystic ovarian syndrome, an endocrine disorder marked by insulin resistance and T2D onset. 11, 12 By re-sequencing the coding region of the MTNR1B gene coding for the MT 2 receptor, 40 variants have been identified and functionally characterized. Corresponding mutants with impaired receptor signaling were strongly associated with the T2D risk, indicating that loss of melatonin receptor function is positively associated with disease risk. 9, 13 A recent study proposed that a common variant (rs10830963) of the MT 2 receptor, which is associated with a modest increase in T2D risk, might be associated with increased MT 2 mRNA expression within pancreatic islets and more pronounced inhibition of insulin secretion.
14 Despite these substantial genetic evidence linking melatonin receptors to diabetes, relatively few studies have characterized mechanisms underlying glucose homeostasis in melatonin receptor knockout (KO) mice. [14] [15] [16] An early report demonstrated that mice lacking MT 1 had higher mean blood glucose levels than wild-type (WT) controls and mice lacking MT 2. 16 A subsequent investigation further established that MT 1 KO mice are glucose intolerant and insulin resistant with respect to both WT and MT 2 KO mice. 15 Finally, the recent study by Tuomi et al 14 reported that although MT 2 KO mice did not show any significant differences in glucose tolerance, they exhibited slightly reduced hepatic insulin sensitivity with respect to WT mice. In the latter study, tissue-specific glucose metabolism was not characterized in MT 1 KO mice. To date, the underlying mechanism by which MT 1 KO mice develop insulin resistance remains largely unknown, and this is compounded by the fact this phenotype occurs during the day when melatonin-the endogenous ligand for MT 1 -is absent. The aim of this study was thus to characterize glucose metabolism in MT 1 KO mice and to investigate the mechanism by which the removal of MT 1 impairs insulin responsiveness during the day.
| RESEARCH DESIGN

AND METHODS
| Animals
Melatonin-proficient (C3H-f+/+ ; WT) and melatonin-proficient mice lacking MT 1 (C3H-f+/+ ; MT 1 KO) were used in this study. 15 Mice (males, 3-5 months) were maintained in a 12-hour light: dark (LD) cycle (lights on at 6 am (denoted as Zeitgeber Time (ZT) 0) and lights off at 6 pm (ZT12), food, and water were available ad libitum. All experimental procedures were performed in accordance with the NIH Guide on Care and Use of Laboratory Animals and were approved by the Morehouse School of Medicine Animal Care and Use Committee.
| Body composition and hyperinsulinemic-euglycemic clamp
Whole-body fat mass and lean mass were noninvasively measured in awake mice fed a normal chow diet using 1 H-MRS (Echo-MRI; Echo Medical Systems, Houston, TX, USA 
| Lipid analysis
Collected blood samples were centrifuged at 3000 g for 10 minutes and the obtained serum stored at −20°C until assayed. Triglycerides, phospholipids, total cholesterol, and nonesterified fatty acids (NEFA) were analyzed spectrophotometrically (SEAC, Florence, Italy) following enzymatic hydrolysis. Briefly, triglycerides were quantified after enzymatic hydrolysis with lipoprotein lipases, phospholipids were quantified following enzymatic hydrolysis with phospholipase D (Centronic GmbH), and total cholesterol was assessed following enzymatic hydrolysis and oxidation. NEFA were measured enzymatically with a commercially available kit (Randox Laboratories). All samples were analyzed in duplicate.
| Western blot
Mice were fasted for 5 hours before intraperitoneal (i.p.) injection with 0.75 U/kg body weight of insulin (Humalog Lilly in 0.9% NaCl) during the day at ZT6, then sacrificed 0-and 15-minutes postinsulin injection. Skeletal muscle, adipose tissue, and liver tissue were collected at each time point and homogenized in lysis buffer (Invitrogen). Following gel electrophoresis and Western blotting, immuno-complexes were visualized using antibodies directed against phospho-AKT (T308) (Cell Signaling Technology # 2965), total AKT (Cell Signaling Technology # 2960), phospho-ERK (Thr202/Tyr204) (Cell Signaling Technology #4370), and total ERK (Cell Signaling Technology # 9102). Bands were developed using nonradioactive-enhanced chemiluminescence system (ECL), and optical densitometry was performed using NIH ImageJ software.
| Glucose tolerance test and insulin tolerance test
WT mice were separated into 3 groups: (i) mice which were kept in the acclimation conditions of 12L:12D; (ii) mice which were exposed to LAN (300-400 lux); and (iii) mice exposed to LAN with melatonin in the drinking water (dissolved in ethanol and diluted 1:1000 with water to a final concentration of 20 μg/mL) from ZT12 to ZT24. The day of the experiment mice were fasted for 5 hours, and at ZT 6, an intraperitoneal insulin tolerance test (IPITT) or intraperitoneal glucose tolerance test (IPGTT) was performed as previously described. 15 Pyruvate tolerance tests (PTT) was performed by injecting (i.p.) 1.5 mg/g body weight of sodium pyruvate (20% sodium pyruvate, Sigma).
| Real-time quantitative-RT-PCR (Q-
PCR)
WT and MT 1 KO mice were sacrificed every 3 hours, from ZT1 to ZT22, and livers were collected and immediately frozen. The daily rhythm in the expression of the regulatory (p50α, p55α, and p85α) and the catalytic subunits (p110α and p110β) that form the PI3K enzyme was determined by quantitative RT-PCR, using specific primers (Table S1 ). Total RNA extraction (Life Technologies), DNase treatment (Promega), and reverse transcription were performed on 1 μg of RNA using a High-Capacity RNA-to-cDNA Kit (Life Technologies), and Q-PCR reactions (iQ SYBR Green Supermix; Bio-Rad Laboratories) were carried out as previously described. 
PIP 3 formation
Mice were injected i.p. with either vehicle (NaCl 0.9%) or insulin (0.75 U/kg body weight; Humalog) and 15 minutes after the injection were anesthetized with isoflurane and perfused with 4% paraformaldehyde. The livers were then explanted and kept overnight in paraformaldehyde. The samples were then transferred to a 30% sucrose solution to cryoprotect the tissue, and thereafter, the samples were imbedded in TissueTek and sectioned at 12 μm using a cryostat. Sections were mounted onto Histobond+ slides (VWR).
PIP 3 levels in the liver were determined using the Mouse on Mouse (M.O.M.) detection Kit following the manufacturer's protocol (Vector Laboratories) as previously described. 19 Samples were blocked with the MOM mouse IgG blocking reagent for 1 hour and treated with MOM diluent for 5 minutes. The slides were then incubated for 30 minutes with the primary antibody (mouse anti-PIP 3 ; Echelon Biosciences Inc.) diluted 1:10 in MOM mouse diluent. Following this, samples were incubated for 10 minutes with the MOM biotinylated anti-mouse IgG solution and the secondary antibody (DyLight Streptavidin 488: Vector Laboratories) was added for 1 hour. Finally, slides were coverslipped with Vectashield and observed with a confocal microscope (Zeiss LSM700).
| Detection of MT 1 mRNA
RNA extraction (TRI ® Reagent method), DNase treatment (Promega), cDNA synthesis, and conventional PCR (One
Step SYBR ® PrimeScript™ RT-PCR kit II, Takara) were carried out following manufacturer instructions. A quantity of 200 ng of RNA was used to perform the one-step PCR reactions that were developed in a final volume of 50 μL. The resulting PCR product (expected sizes are 137 and 123 bp for MT 1 and 18S, respectively) was run in an agarose 1.5% TAE gel and visualize using the EZvision kit (Amresco) in an UV transilluminator.
| Gene expression omnibus (GEO) analysis
To investigate the clinical implications of MT 1 in the regulation of insulin sensitivity, we utilized the GEO software available through NCBI to browse datasets related to insulin resistance and diabetes. From the sets identified, microarray dataset GDS3876 was chosen based on tissue-specific examination of the liver and its inclusion of both diabetic and nondiabetic samples. Within this cohort, obese subjects were significantly more insulin resistant than lean controls. For more details on the clinical features of this cohort, please refer to ref (25) . To determine the correlation of melatonin expression levels with clinical features such obesity and disease state, the GEO profile was queried for dataset-specific gene expression profiles for MTNR1A (MT1), then stratified according to individual phenotype (lean; obese) and disease state (non-T2D, T2D well controlled (T2D WC), T2D poorly controlled (T2D PC)).
| Data analysis
Results are presented as mean ± standard error of the mean (SEM) and were considered significant when P < .05. COSINOR analysis was performed using the nonlinear regression model within SigmaPlot V 10.0 (Systat Software, San Jose, CA, USA as described in ref. 18 ). Statistical analysis was performed using the Student's t test or a one-way analysis of variance (ANOVA) and post hoc Holm-Sidak test.
3 | RESULTS
| MT 1 KO mice exhibit systemic insulin resistance in the absence of dyslipidemia
Increased adiposity has been linked to insulin resistance and abnormal glucose metabolism. 17 Therefore, we first examined the relationship between fat mass and insulin sensitivity in WT and MT 1 KO mice. MT 1 KO mice had slightly higher body weight (10%) than WT mice ( Figure 1A ). This was largely due to increased fat mass (30%, P < .052) in MT 1 KO mice as whole-body lean mass did not differ between groups. Increased obesity in MT 1 KO mice was not attributed to changes in physical activity or daily food intake. 20 Subsequent analysis of plasma lipids in MT 1 KO mice revealed significantly lower levels of triglycerides, phospholipids, and free fatty acids, in the presence of moderately elevated LDL cholesterol levels ( Figure 1B-D with insulin resistance 21, 22 and collectively suggest that the deletion of MT 1 beneficially affects lipid metabolism.
To gain a better understanding of the mechanisms underlying insulin resistance in MT 1 KO mice (see Figure 2A ,B), we performed hyperinsulinemic-euglycemic clamp studies in WT and MT 1 KO mice (see Figure 2D -F and Table S2 ). MT 1 KO mice required a substantially lower glucose infusion rate (GIR) to maintain euglycemia during the clamp and exhibited decreased rates of glucose turnover compared to WT mice ( Figure 2D) . At the tissue level, decreased insulin sensitivity in MT 1 KO mice was mostly attributed to significant reductions in insulin-stimulated glucose uptake in skeletal muscle and white adipose tissue ( Figure 2E ). Additionally, pyruvate tolerance as well as insulin-mediated suppression of hepatic glucose production (HGP) during the clamp was significantly impaired in MT 1 KO mice ( Figure 2C,D) . Consistent with a classical insulin-resistant phenotype, MT 1 KO mice also exhibited substantial impairments in whole-body glycogen synthesis ( Figure 2F ). Taken together these data point to the existence of a generalized mechanism by which the loss of MT 1 affects insulin sensitivity in multiple insulin-responsive organs.
| MT 1 KO mice exhibit impaired insulin signaling in vivo
One of the driving forces for the alteration of the glucose control in MT 1 KO mice was the loss of insulin sensitivity within the liver-as demonstrated by the complete inability of MT 1 KO mice to suppress hepatic glucose production ( Figure 2D ). To determine how the loss of MT 1 could generate such generalized systemic impairments in insulin sensitivity, we next investigated whether these defects were directly linked to alterations in the insulin signaling pathway in the liver where MT 1 receptors are expressed (see Figure  S1 ). To test this hypothesis, we evaluated the activation of 2 key downstream effectors of insulin signaling-protein kinase B (AKT) and extracellular signal-regulated kinase (ERK)-within the liver. As shown in Figure 3 , the phosphorylation (Threonine 308) of AKT in response to an i.p. injection of insulin (0.75 units/kg) at ZT6 was significantly impaired within liver of MT 1 KO mice, whereas there were no clear differences in the activation of the phospho-ERK pathway in response to insulin. Hence, our data suggest that the loss of MT 1 impairs the ability of insulin to activate the AKT pathway within the liver. PI3K generates phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ), a second messenger essential for both the plasma membrane translocation and activation of AKT. 24 To evaluate PI3K activity, WT and MT 1 KO mice were injected with insulin or vehicle during the day at ZT6 and the activity of PI3K-measured as PIP 3 production-was assessed within the liver 15-minutes postinsulin injection. As shown in Figure 4 , PIP 3 production showed an increase in WT but not in MT 1 KO mice. Vehicle injection did not affect PIP 3 production within either genotype (Figure 4 ). At this point, it was unclear whether MT 1 could directly regulate the activation of PI3K; or given its nocturnal activation profile, possibly confers more indirect effects by regulating steady-state transcriptional levels of PI3K. Hence, to investigate whether the regulation of PI3K by MT 1 occurs at the transcriptional level, we examined the daily rhythm in the 5 subunits (p50α, p55α, p85α, p110α, and p110β) which compose PI3K. 24 Our data indicate that within MT 1 KO mice p50α, p55α, p85α, and p110α, mRNA levels were no longer rhythmic and significantly reduced ( Figure 5 and Table  S3 ). Interestingly, steady-state levels of the p110β subunit were increased by the deletion of MT 1 . Collectively these data suggest that MT 1 regulates PI3K-at least in part-via the transcriptional regulation of its catalytic and regulatory subunits.
| The nocturnal rise in melatonin levels is necessary and sufficient for the modulation of insulin sensitivity during the day
The fact that the insulin signaling is affected in MT 1 KO mice during the light period, when melatonin levels in the blood are undetectable, prompted us to investigate whether the activation of MT 1 signaling at night is required and sufficient to modulate insulin signaling during the day.
To determine whether the presence of the nocturnal peak in melatonin level at night is required to modulate insulin sensitivity during the day, we exposed WT mice to light during the night (LAN) in order to inhibit nocturnal melatonin synthesis, 5 and then on the following day performed an IPITT at ZT 6. As shown in Figure 6 , WT mice exposed to LAN showed a significant decrease in insulin sensitivity that mimics what was observed in MT 1 KO mice ( Figures 2B  and 4 ). To determine whether the activation of MT 1 at night was sufficient to modulate insulin sensitivity during the day (i.e, to exclude that the exposure to light would have an effect on insulin sensitivity independently from melatonin), we exposed WT mice to LAN again, but this time, we supplemented the drinking water with melatonin (20 μg/mL) during the night (from ZT12 to ZT0) to restore the nocturnal peak in melatonin levels. As shown in Figure 6 , the supplementation with melatonin of mice exposed to constant light during the night restored insulin sensitivity, the next day at ZT6, to the same magnitude as WT mice exposed to a normal dark-light cycle. We then investigated whether the changes in insulin sensitivity were linked to changes in PI3K activity. As shown in Figure 6C , insulin injection failed to increase PIP 3 production in WT mice exposed to LAN, whereas insulin injection in WT mice exposed to LAN, with melatonin supplementation, induced an increase in the PIP 3 production ( Figure 6C ). Exposure to LAN and LAN plus melatonin in MT 1 KO did not produce any changes in the IPITT or PI3K (Figure 6D,E) . Lastly, we investigated whether MT 1 gene expression was affected in insulin-resistant/T2D individuals. Using the GEO microarray dataset GDS3876, 25 we were able to generate an expression profile for MTNR1A (MT 1 ) in the liver of non-T2D and T2D individuals. The most striking finding from this analysis was that liver MTNR1A expression levels were significantly reduced in T2D patients with poorly controlled diabetes (HbA1c >7.9; fasting glucose >9 (mmol/liter), HOMA-IR >20, see ref. 25 for details) ( Figure 7B ). Hence, these data further suggest that the loss of MT 1 signaling may also be involved in the regulation of glucose metabolism in humans.
| DISCUSSION
Type 2 diabetes is an endocrine disorder whose frequency has been increasing at alarming rates worldwide. 26 A number of studies have now linked melatonin receptors to the pathogenesis of T2D, 4, [9] [10] [11] [12] 14 with the majority of these works identifying altered MT 2 signaling as a significant risk factor for disease progression. 13 Currently, little is known about the role of MT 1 in the regulation of glucose metabolism or its direct involvement in the pathogenesis of T2D. To this end, we have previously reported that MT 1 KO mice display impairments in glucose metabolism; 15, 18 however, the mechanisms underlying this phenotype remain poorly understood.
In the current study, we sought to further dissect this phenotype by performing hyperinsulinemic-euglycemic clamp studies in WT and MT 1 KO mice. Examination of tissuespecific insulin action revealed that MT 1 KO mice display systemic insulin resistance as demonstrated by a diminished insulin response in skeletal muscle, white adipose tissue, and the liver (Figure 2) . Notably, the most striking effect was the inability of insulin to suppress hepatic glucose production ( Figure 2D ). These changes in glucose metabolism were not accompanied by changes in fasting insulin or glucose levels (Table S2) , suggesting a phenotype reflective of alterations in insulin sensitivity as opposed to insulin secretion. Increased adipose mass affects insulin sensitivity by increasing free fatty acid flux to other metabolic organs thereby producing insulin resistance as a result of "lipotoxicity". 27 Interestingly we observed a modest increase in weight and fat mass of MT 1 KO mice. This result differs from earlier works which we and others reported no difference in weight among WT and MT 1 KO mice. 15, 16 The discrepancy appears to correlate with the age of the mice when the studies were conducted (3 months vs 5 months of age), suggesting that the effect of MT 1 on fat mass becomes more prominent as animals age. T2D has been associated with dyslipidemia marked by elevated free fatty acids and triglycerides, reduced HDL cholesterol, and an increased number of small dense LDL particles. 22 MT 1 KO mice displayed significantly decreased levels of circulating triglycerides, phospholipids, and free fatty acids (Figure 1) . Therefore, although these mice exhibit clear alterations in their lipid profiles, it leans toward a more "beneficial" lipid profile and highlights a potential role for MT 1 in lipoprotein metabolism. These results also indicate that insulin resistance in MT 1 KO mice is not dependent on changes in lipid metabolism. Further studies would be needed to characterize the modest increase in LDL levels observed within MT 1 KO mice. AKT is a critical component of the insulin signaling pathway and as such is involved in the regulation of glucose metabolism. 28 Our data demonstrate that the loss of MT 1 impairs the activation of AKT in key metabolic organs (i.e, liver; Figure 3 ). Moreover, MT 1 KO mice display stark impairments upstream of AKT at the level of PI3K activity and the transcriptional regulation of its subunits within the liver (Figures 4 and 5) . PI3K is composed of both regulatory (p85α and p50α) and catalytic (p110α, p110β, and p100γ) subunits which combine to form a functional heterodimer. Within the body, the majority of tissues will express heterodimers composed of p85α and p110α. 22, 24 A number of studies have now shed light on the relative importance of these subunits in the regulation of insulin sensitivity (24) (25) (26) . Mice lacking p85α exhibit reduced PI3K activity in response to insulin, 19 whereas mice carrying a mutant copy of p110α (p110αD933A) are both insulin resistant and glucose intolerant. 29 Furthermore, when the gene encoding for p110α is conditionally inactivated within the liver, these mice display substantial impairment of AKT phosphorylation. 30 Subsequently, other studies have demonstrated that the lack of p110α in the liver had little effect on insulin sensitivity and glucose tolerance in mice. 31 Thus, our results demonstrating that the daily mRNA expressions of p50α, p55α, p85α, and p110α are no longer rhythmic and significantly downregulated ( Figure 5 and Table S3 ), establish that the lack of MT 1 signaling affects the transcription of these subunits and may consequently lead to a nonoptimal assembly of the PI3K complex. Interestingly, the insulin-resistant phenotype observed in MT 1 KO mice was recapitulated in WT mice by inhibiting the nocturnal surge of melatonin through exposure to one night of LAN. This effect could subsequently be rescued by restoring nocturnal melatonin to physiological levels through melatonin supplementation in drinking water. 32 MT 2 does not appear to be involved in this response, as MT 2 KO mice do not show pronounced insulin resistance. 15 Collectively, these data indicate that the nocturnal surge of melatonin is both necessary and sufficient to modulate insulin sensitivity during the day. To date, only few studies have reported that melatonin is capable of providing a "dark priming" signal which can confer signaling outcomes long after melatonin is removed from circulation. Classical examples of this "dark priming mechanism" by melatonin are illustrated by the regulation of daily rhythms F I G U R E 6 The nocturnal rise in melatonin is sufficient and necessary to modulate insulin sensitivity during the day. WT mice were exposed to LD, LAN, or LAN+MEL for 24 hours. A, IPITT test was performed on ZT 6 of the following day. Data obtained are expressed as mean ± SEM (n = 7-10). When significant (ANOVA P < .05), differences among groups are indicated by an asterisk (Holm-Sidak test). B, Calculated area under the curve (AUC) for IPITT's. C, WT mice were injected with either vehicle or insulin (0.75 U/kg body weight) at ZT 6, and PIP 3 in disk shedding/phagocytosis within the retina 33 and in the modulation of the daily rhythms in light-induced damage of retinal photoreceptors. 34 Moreover, within the pituitary, the nocturnal activation of MT 1 receptors is necessary to sensitize the adenosine A2b receptor to effectively respond to adenosine during the day. 35 Our data for the first time highlight that such "dark priming mechanisms" may regulate insulin sensitivity, as all of the effects observed within MT 1 KO mice occurred during the day in the absence of melatonin. This study also provides insight into a potential mechanism via which shift-work can result in the development of insulin resistance, obesity, and diabetes.
Finally, our data demonstrate that a significant decrease in MTRN1A mRNA levels is present in diabetic patients with poor glucose control thus suggesting that human MT 1 signaling may be involved in the control of glucose metabolism.
A recent human study observed that acute melatonin administration functions to worsen rather than improve glucose tolerance and insulin resistance. 36 This in contrast to what we observed in the current study, in which we found that in mice, nocturnal melatonin supplementation improved insulin sensitivity. We have demonstrated that melatonin likely imparts its effects on insulin sensitivity through a mechanism which involves nocturnal priming and long-term transcriptional changes. Therefore, one may speculate that the immediate effects likely mediated by the direct activation of MT 1 and MT 2 receptors via melatonin may differ from transcriptional changes initiated long after receptor activation. Contrasting results from a number of studies comparing melatonin supplementation in humans vs mice further serve to highlight the complexity of the melatonergic system. Indeed, it must be noted that in rodents melatonin secretion occurs during physical activity whereas in rodents it coincides with the sleep phase.
In conclusion, our data demonstrate that the nocturnal increase in melatonin levels and consequent activation of MT 1 signaling modulate insulin sensitivity on the following day via the transcriptional regulation of PI3K subunits and thus PI3K activity (Figure 8 ). In addition, our studies F I G U R E 7 MTNR1A mRNA is reduced in the liver of T2D patients with poorly controlled diabetes. Microarray gene expression data were downloaded from the NCBI GEO database GDS3876. MTNR1A levels were assessed by comparing obesity (A) and disease state (B). T2D WC: T2D well controlled. T2D PC: T2D poorly controlled. *P < .05, t test (T2D WC vs T2D PC). Lean (n = 5), obese (n = 4), nondiabetic (n = 9), T2D WC (n = 5), T2D PC (n = 4) F I G U R E 8 Schematic model describing the possible pathway by which melatonin via MT 1 modulates insulin sensitivity. The nocturnal increases in melatonin levels during the night activated MT 1 signaling which affects the transcription of the genes that are responsible for the assembly and the activity of P13K and thus glucose uptake underscore the complexity of the mammalian circadian system by demonstrating that dysfunction of the brain circadian system (i.e, the SCN, pineal, and melatonin axis) is capable of producing significant effects in peripheral tissues even though circadian clocks within these tissues may appear to be unaffected.
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